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EXECUTIVE SUMMARY 
Regenerative Medicine has the potential to be a game-changer for patients who have damaged 
tissues or organs due to untreatable diseases, injuries, and congenital conditions. Lab-based 
innovations have shown great promise in restoring structure and function, but to deliver 
treatments to large numbers of patients in a clinical setting, new tools and technologies are 
needed. Regenerative Medicine is a new area of medical research that seeks to automate and 
scale-up the production and deployment of these groundbreaking solutions. 
The technologies discussed in this report are intentionally pre-competitive, meaning that the 
Federal Government may choose to play a role in additional growth via well-informed initiatives. 
Governmental support can come in the form of additional research & development (R&D) 
dollars that are magnified by private co-investment, or can be in the form of non-pecuniary 
actions such as modifications to the regulatory environment to better support this rapidly 
changing field. Ideally, a cooperative relationship between government and private industry will 
result in cross-industry, pre-competitive tools that decrease development cost and time while 
still respecting individual intellectual property ownership within a competitive environment.   
This report identifies promising biomanufacturing platforms that will provide a foundation for the 
automation and standardization of the processes associated with successful scale-up and 
scale-out. After evaluating a range of potential translational technology options according to 
their suitability for co-investment and cross-industry appeal, two platform technologies and two 
enabling tools were selected: 
PLATFORM TECHNOLOGY #1: 3D CONSTRUCTS, INCLUDING ORGANOIDS, SCAFFOLDS, AND PRINTED TISSUES 
Based on the potential for patient-specific applications, 3D Constructs, including Organoids, 
Scaffolds, and Printed Tissues were selected as a key platform technology. 3D constructs are 
predicted to be a critical component of cell-based therapies for tissue- and organ-based 
regenerative approaches. The resulting three-dimensional structures can be used for the 
treatment of congenital conditions, and can treat tissue loss due to cancer or trauma.   
PLATFORM TECHNOLOGY #2: BIOMANUFACTURING PROCESSES 
Given the inherent process management challenges encountered when manipulating cells and 
biological tissues, the development of stable, consistent and safe Biomanufacturing Processes 
is a key platform in Regenerative Medicine.  
Because of the range of topics under the heading “Biomanufacturing Processes,” the area was 
further divided into two key enabling tools:   
(i) Scaled-up bioreactors for cell culture, and  
(ii) Improvements in cell harvesting, cell processing, and preservation technologies; 
each directly affecting the supply of materials to the production process, and 
therefore requiring high-level management.  
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SUMMARY OF KEY OBSERVATIONS 
• Pre-competitive and core technology development should be kept as open as possible to sustain 
the network effect gained from using standard biological platforms, data systems, and 
manufacturing and testing standards.   
• Government should consider/nurture/recognize different models for technology 
commercialization. This would allow for the creation of ecosystems that bring academic, 
government, and industrial partners together in highly integrated environments that facilitate the 
engagement of commercialization teams in bio-product development at a very early stage.  
• The ideal partnership for research institutions working with early-stage technologies is with an 
enterprise that has strong translational capabilities. 
• The failure of large corporations to fully embrace many Regenerative Medicine products and 
technologies is a major barrier to investment for many small companies. Government can 
mitigate these barriers with reforms to the regulatory environment that improve clarity and 
timeliness to market, thereby de-risking and encouraging corporate investment. 
• Many university tech transfer offices do not understand the complexities of maturing a technology 
into a market-ready state, causing an overvaluation of early-stage discoveries.   
• NIST, federal regulators, industry and academic leaders should work together to establish 
relevant standards. One approach is to embed regulatory personnel within companies during the 
pre-competitive development process. The result will be regulations that are more suitably 
targeted to the technology under development. 
• More flexible regulatory mechanisms could help accelerate Regenerative Medicine product 
development, particularly in the area of manufacturing process development. 
• There is a need for enhanced development on process engineering, manufacturing, and more 
cost-effective clinical trials. The current status is seen as a major U.S. disadvantage and a 
serious obstacle to commercialization. 
• Scientific researchers must collaborate with ethicists to be sure that all R&D work follows the 
highest ethical standards. Furthermore, experienced scientific researchers should take the lead in 
using science-based data to underscore the potential benefits of Regenerative Medicine to the 
public.  
• New employees at biotechnology firms can require significant time (up to 2 years) to gain an 
understanding of core concepts. To meet the workforce challenges at various levels, universities 
should consider creating new certificate or degree programs in bioprocess engineering (directed 
toward cell therapy). Public/private consortia should be involved in developing curricula for these 
programs. Additionally, there is an acknowledged need for new associate-level training for 
operators working in clean room environments.  
• Workforce development programs should include practical training through industry internships 
and apprenticeships, as well as undergraduate, graduate and post-doc research fellowships at 
national labs. 
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INTRODUCTION 
Medicine has advanced in astounding ways over the course of the past century. With the 
development of drugs and technologies ranging from Penicillin and vaccines to modern X-rays 
and anesthesia, the average life expectancy at birth in the U.S. increased from under 50 years 
in 19001 to almost 80 years today.2 A range of pernicious and previously untreatable diseases 
from polio to juvenile diabetes to various forms of cancer have finally become manageable or 
beatable due to the immense focused attention of medical researchers and practitioners.  
The cumulative result of academic, governmental, and private medical research investments 
has been a massive flourishing of human life. Yet there is reason to believe that advances in 
medical technology in the decades to come could tower over the last century’s innovations.  
A case in point is the development of the new field of Regenerative Medicine (RM). This 
emerging area of research could revolutionize the treatment of diseases, injuries, and 
congenital conditions by turning various basic tissues into fully functional human organs.  
Regenerative Medicine combines diverse innovations to enable the use of bodily tissues like 
progenitor cells (from umbilical cord blood) or stem cells (from adults or embryos) to repair or 
replace failing systems in a human body. The operating principle behind Regenerative Medicine 
is simple and profound: 
 The human body can heal itself.  
For people living with untreatable conditions or with loved ones coping with disease or injury, 
these innovations cannot come quickly enough. But there are serious hurdles that must be 
overcome before regenerative therapies can go mainstream.  
To bring Regenerative Medicine to scale, smart investments in translational research are 
necessary to bring laboratory discoveries all the way to operating rooms. It is not enough to do 
the needed work in the lab or in product rollout — we need focused thinking and action to 
connect the “R” with the “D” of the R&D equation, translating initial discoveries and innovations 
into life-saving products and processes.  
In spite of the ongoing work in the field of Regenerative Medicine,3 research is only part of the 
challenge. It is also necessary to address underlying needs related to training the Regenerative 
Medicine workforce, designing prudent regulations, perfecting university technology transfer 
protocols, and forming new standards and guidelines for the ethical use of these transformative 
technologies.  
                                                
1  Centers for Disease Control and Prevention. U.S. Decennial Life Tables for 1890 to 1961. 
http://www.cdc.gov/nchs/products/life_tables.htm#1890_1961.  
2  CIA. The World Factbook. Life Expectancy at Birth. https://www.cia.gov/library/publications/the-world-
factbook/rankorder/2102rank.html.  
3 Between January 2012 and September 2013, Web of Knowledge database cites over 8000 original publications for 
tissue engineering or regenerative medicine. 
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ABOUT THIS REPORT  
This report offers specific details on the partnerships, analyses, and investments that 
government, private sector, and university stakeholders can undertake to enable the prompt and 
safe development of Regenerative Medicine technologies.  
From the development of 3D medical constructs to the creation of clear process standards for 
manufacturing and clinical environments, the recommendations follow a common thread: 
Regenerative Medicine can benefit from cross-sector collaboration to create pre-competitive 
tools to decrease development cost and time to market. These recommendations,  based on 
inputs from subject matter experts , emphasize that carefully targeted research cooperation and 
coordination on workforce training can succeed without undercutting market forces.  
The approach taken to develop this report includes:  
1. The use of Technology Readiness Level (TRL) 4 indicators to identify today’s promising 
translational platform technologies in Regenerative Medicine. 
2. An identification of key barriers to translation at the interface of discovery, 
manufacturing, and clinical administration, including regulatory, technology transfer, and 
intellectual property barriers. 
3. The selection of the critical advancements needed at biomanufacturing facilities to 
achieve commercial and technical viability.  
4. An exploration of successful models of industry-government collaborations on the 
creation of non-competitive platform technologies to support future underlying 
therapeutic advancement to commercialization. 
5. A discussion on the ideal R&D partnership model between academia, industry, and 
government, and an assessment of how Federal Government participation can minimize 
risks during the technology development process.   
6. A look at U.S. competitiveness to ensure that manufacturing of RM technologies remains 
in the U.S., and to assess incurred challenges and opportunities in education and 
workforce training. 
Of special note is the focus on technologies that are beyond the basic research stage, but not 
yet commercial. Referred to as translational, the selected technologies have Technology 
Readiness Levels ranging from TRL4 (component-level validation in the laboratory) to TRL7 
(system prototype in an operational environment). This range of technological maturity is 
considered to have the greatest potential for transforming the manufacturing of RM therapies, 
but still face significant barriers to adoption. 
The therapeutic platforms under consideration can be broadly characterized according to their 
ability to impact our understanding and proficiency in: 
                                                
4 Technology Readiness Levels (TRL) are used to assess the maturity level of a particular technology. TRL1 is the 
lowest level (initial scientific research) and TRL9 is the highest (successful operational use.) See 
http://www.ncbi.nlm.nih.gov/books/NBK201356. 
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• Regulating the immune system; 
• Directing or controlling cellular differentiation; 
• Engineering and growing functional 3D structures and organ systems; and 
• Delivering agents directly to cells. 
The manufacturing and enabling platforms of interest allow for the automation and 
standardization of several of the processes associated with scaling-up and scaling-out these 
technologies to effectively reach the potential of broader impact. 
   
TARGET AUDIENCE 
The goal of this report is to inform policy makers, funding agencies, and private investors about 
technology opportunities that can advance the field of Regenerative Medicine. The conclusions 
will be useful for professionals working across the field of Regenerative Medicine, including 
program managers at various federal agencies as well as researchers across various industry 
sectors, academia and federal laboratories – with a special focus on those readers who deal 
with medical innovations in the translational stage of development. 
 
BACKGROUND ON REGENERATIVE MEDICINE 
Regenerative Medicine focuses on the replacement of damaged or diseased organs and other 
bodily structures through the engineering of cells and tissues. It combines the technical 
expertise of biologists, geneticists, engineers and medical researchers. Research approaches in 
this field are diverse, including cellular and molecular pathways, growth factor biology, 
biomaterials, and pharmacology and drug delivery.  
The basic idea of tissue replacement is not new. Humans have long sought to develop better 
surgical procedures and materials to replace or return damaged tissues to their normal function. 
In the distant past, only indigenous materials were available to repair injuries and defects. 
Evidence dating back to the Neolithic age reveals a Peruvian tribal chief whose frontal bone 
defect had been repaired by a gold plate applied with a hammer.5 Skin grafts composed of free 
gluteal fat were first used to treat mutilations of the ear, nose, and lip as early as 2500 BCE.6 
Ancient Hindu texts written between 3500 and 1800 BCE chronicle Queen Vishpla, a warrior 
who lost her leg in battle and had it replaced with an iron limb before returning to battle.7  
In modern times, the concept of tissue replacement has expanded to include tissue 
regeneration. Regeneration leverages the body’s natural ability to heal, or uses of specific types 
of cells to restore tissue and organ function. The Regenerative Medicine toolkit is diverse, and 
                                                
5 Donati, D., Zolezzi, C., Tomba, P. and Viganò, A. (2007). Bone grafting: historical and conceptual review, starting 
with an old manuscript by Vittorio Putti. Acta Orthopaedica, 78(1), pp.19-25. 
6 Kaul, H. and Ventikos, Y. (2015). On the Genealogy of Tissue Engineering and Regenerative Medicine. Tissue 
Engineering Part B: Reviews, 21(2), pp.203-217. 
7 Srivastava, K., & Chaudhury, S. (2014). Rehabilitation after amputation: Psychotherapeutic intervention module in 
indian scenario. The Scientific World Journal, http://dx.doi.org/10.1155/2014/469385. 
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includes: cells (particularly stem cells), natural and synthetic controlled release matrices, 
scaffolds, and soluble molecules to direct cell function (nucleic acids, proteins, hormones, and 
viruses). 
This paradigm shift from substitution to regeneration is the defining impetus for further 
developments in tissue engineering and regenerative medicine. Tissue engineering involves the 
manipulation of artificial materials, not only to assist cells in reconstruction, regeneration, and 
repair of damaged tissue, but also to restore lost function.   
The term Regenerative Medicine is often used interchangeably with tissue engineering, 
especially denoting the addition of stem cells and permanent/transient cell-replacement 
therapies. Regenerative Medicine can use a variety of cell types ranging from stem cells (adult 
and embryonic), progenitor cells (from umbilical cord blood) and induced pluripotent stem cells 
(iPSC), which are bioengineered cell structures. Cells are often combined with biologically 
compatible scaffolds to replicate damaged or diseased structures in the body. Working with the 
body’s ability to heal itself, new tissue can be stimulated to grow into a fully functional 
replacement body structure. Both allogeneic and autologous cells can be used as foundational 
cells from which larger tissue structures can be built.  
 
ADVANCING THE FIELD OF REGENERATIVE MEDICINE 
To move promising research results from “bench to bed,”8 crosscutting translational research is 
needed so that lab-based technology can be matured into practical and commercially viable 
products. Specifically, tools and technology are needed that automate and scale-up the 
production and deployment of Regenerative Medicine advances. In addition, a new generation 
of workers will require training in critical skills to operate bio-factories safely and cost-effectively. 
Targeted investment in translational research will result in new regenerative therapies reaching 
patients across the world. 
While it is clear that the basic science of Regenerative Medicine has led to a wide assortment of 
published findings and documents, 9  the rate of significant translation from laboratory 
experiments to broad applications has been comparatively lower.10 This leaves many to ask the 
question: What technological advances are needed to accelerate the transition of 
scientific discoveries from lab to patients? 
To gain insight into this question, a structured evaluation process was followed that weighs and 
filters specific translational technologies according to pre-defined criteria. The process starts by 
selecting promising platform technologies (both manufacturing and therapeutic) that are likely to 
                                                
8 The expression “bench to bed” refers to the multi-step transition from basic research and translational engineering 
(the “bench”) to clinical use (the “bed”).  
9 Harrison, R., St-Pierre, J. and Stevens, M. (2014). Tissue Engineering and Regenerative Medicine: A Year in 
Review. Tissue Engineering Part B: Reviews, 20(1), pp.1-16. 
10  van Osch, G., Burdick, J. and Liu, W. (2014). Emerging Issues in Translating Laboratory Experiments to 
Applications for Society. Tissue Engineering Part A, 20(19-20), pp.2547-2548. 
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have an impact on health outcomes and economic growth over the next 5-10 years.11 The 
candidate technologies were sorted and filtered according to economic and technical maturity 
criteria to identify “Key Translational” technologies. 
Note, however, that progress in technology readiness is not necessarily synonymous with 
progress in manufacturing readiness,12 which is defined to be “the ability for products to be 
manufactured in an affordable, operationally effective manner”. 13  For any given 
innovation/technology, advancing its overall readiness requires improvements in both 
therapeutic platform technologies and manufacturing platform technologies.   
The interplay between technology readiness and manufacturing readiness is characteristic to 
most rapidly advancing technologies, and is particularly important during the translational 
development process. 
This concept is shown in 
Figure 1, where 
therapeutic platform 
innovations (such as 
immunotherapies and 
cell-based R&D) will 
complement new 
innovations in the 
manufacturing platforms 
(such as bioreactors, 
material preservation and 
process control). The 
concept of dual 
technology-development 
tracks is a strong 
characteristic in an 
interdisciplinary field such 
as regenerative 
medicine, and presents 
unique challenges to 
successful 
commercialization. 
                                                
11 Platform technologies are the foundation for multiple applications, allowing developers avoid the development of a 
tissue or organ from scratch.  
12 The Manufacturing Readiness Level (MRL) assessment was developed by the US Department of Defense to 
assess maturity and identify technology risks from a broader manufacturing perspective.   
13 Wu, C., Wang, B., Zhang, C., Wysk, R. and Chen, Y. (2016). Bioprinting: an assessment based on manufacturing 
readiness levels. Critical Reviews in Biotechnology, pp.1-22. 
Figure 1: Simultaneous advances in therapeutic and manufacturing platforms 
are needed to enable biomanufacturing of RM 
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Figure 2 outlines some of the barriers encountered during the transition from “bench” (basic 
research and translational engineering) to “bed” (clinical use). Specific development barriers 
exist during each of the three key phases of development: 1) scientific discovery, 2) 
biomanufacturing (in an industrial setting) and 3) clinical administration. Once a technology has 
navigated the development path to the patient, many on-going barriers need to be addressed to 
ensure efficacy, safety and security. These barriers include the establishment of facilities that 
meet Good Manufacturing Practices (GMP/cGMP), application of appropriate FDA regulations, 
a supply chain of consistent biomaterials and a business model that allows for continued 
innovation and refinement of new Regenerative Medicine technologies. An example of the 
overlap between different barriers is with the current development in iPSCs.14 An initial funding 
tranche for iPSCs will set the pace and enable discovery of molecular pathways controlling stem 
                                                
14  A more in-depth discussion of the readiness of iPSC therapies for commercialization is addressed in Other 
Technologies section of the report. 
Figure 2: Barriers to translation are encountered at each stage of development 
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cell differentiation, function, and fate. As these new pathways are used in therapies to advance 
through the stage of proof-of-concept (TRL levels 1-3), another funding barrier must be 
overcome to ensure the consistent and predictable large-scale production of stem cell products 
– for example, the creation of iPSCs for cell banking. Once development enters the translational 
stage, the goal is not simply to achieve mass production of cells (a numbers game), but also to 
understand and control the processing conditions that ultimately impact quality and consistency 
of the desired product outcome (TRL 4-7). At the point of readiness for clinical administration 
(TRL 8), barriers such as insufficient safety and limited efficacy clinical trial data can influence 
public opinion and attitudes of providers toward the adoption of these new therapies. For each 
stage leading to commercialization, the challenge of reliable and safe cell-harvesting, -
processing, and -preservation, as well as the requirement for compliant facilities, regulatory 
issues, and cost-effectiveness concerns need be addressed and overcome. 
IDENTIFYING TRANSLATIONAL TECHNOLOGIES 
The process shown in Figure 3 was followed to identify key translational technologies in 
Regenerative Medicine:   
1) A questionnaire was developed that covered a range of topics related to technical maturity, 
scale-up/scale out of translational platform technologies, private sector investment, 
regulations, technology transfer, workforce development and international benchmarking.  
2) Based on recent academic, industry and government reports, a panel of nine national 
thought-leaders in the field of Regenerative Medicine was assembled. The Panel Experts 
supplied detailed answers to questions to the questionnaire in (1) to determine the 
candidate platform technologies. Additional experts were also consulted and are listed as 
Contributors at the end of the report. 
 
Figure 3: MForesight process 
 
3) Two primary criteria were used to filter the full set of translational technologies:  
• Crosscutting Appeal: The first criterion is to select those platform technologies in 
Regenerative Medicine that will be applied most broadly to the industry and also to the 
consumer. Crosscutting appeal leads to a larger market potential, thereby generating a 
future economic benefit that warrants government investment. 
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• Co-Investment Potential: The second criterion is whether private industry would be likely 
to co-invest with the Federal Government in the platform technology under 
consideration. The desire is to find platform technologies that are highly desirable across 
the industry, but are not sufficiently mature to warrant purely private investment.    
The Panel Experts discussed various barriers that these technologies may face, including 
but not limited to: intellectual property (IP), technology transfer, regulations, and irregular 
funding patterns. Additional considerations include economic impact, job growth, and the 
likelihood of the U.S. gaining a first-mover advantage.  
4) Data on candidate technologies was refined 
and ranked according to the crosscutting and 
co-investment criteria mentioned above. 
Virtual roundtables were conducted that 
allowed all participants to understand the 
trade-offs between different translational 
technologies, and to ultimately select those 
technologies that best meet the criteria listed 
above. See Figure 4. 
5) Additional phone interviews with subject 
matter experts were conducted to clarify 
some of the points raised at the roundtable, 
and to seek more holistic responses on 
specific topics. 
SELECTION OF TRANSLATIONAL PLATFORM 
TECHNOLOGIES 
The primary objective for this report is to identify 
translational platform technologies in 
Regenerative Medicine that will enable 
biomanufacturing (scale-up and scale out) and 
offer improvements in health outcomes, and 
positive economic benefits over the next 5 to 10 
years.   
As part of the questionnaire, the Panel Experts 
were asked the following: 
Q1: Please identify the promising platform technologies (both in manufacturing and in 
therapeutics) in your field that you feel will have the maximum impact in health outcomes 
and economic growth over the next 5-10 years. 
Table 1 provides a listing of the nine (9) emerging technologies identified by the Panel Experts 
(A-G) in response to Question 1. The technologies shown in Table 1 represent a broad cross 
section of platform/enabling technologies in Regenerative Medicine that have matured beyond 
the basic research stage and are ready for translational R&D. 
Figure 4: Key translational platform technologies were 
selected using specific criteria 
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Table 1: Translational platform technologies and expert poll results 
REFINING THE LIST OF TRANSLATIONAL PLATFORMS 
To identify the manufacturing and therapeutic platforms with the most potential for 
revolutionizing regenerative therapies, Panel Experts ranked and prioritized the technologies in 
Table 1. Based on their poll, two platform technologies were identified as the front-runners: 
Technology #5 and Technology #8.  
Several enabling tools were also identified that will be needed to fully support progress with 
Technology #5: Bioreactor scale-up (Tech. #1) and Cell processing and harvesting (Tech. #3) 
Bioreactor scale-up involves the use of single-use bioreactors for cell culture (as opposed to 
bioreactors for secreted proteins). Cell processing and harvesting technologies involve the safe 
harvesting and storage of functional tissues, and includes topics such as cryo-preservation and 
bio-preservation of materials, especially at room temperature. Figure 5 illustrates how the 
enabling tools support Technology #5, Biomanufacturing Processes. 
Other technologies listed in Table 1 deemed worthy of discussion include: Immunotherapeutic 
Technologies, Fill and Finish Technologies and Stem Cell Therapies. These topics are 
discussed in the “Other Technologies” section below, along with a brief explanation as to why 
each topic was not a top selection. 
# Technology
A B C D E F G
1 Bioreactor scale-up technologies:  single-use bioreactors for cells (as opposed to secreted proteins); platforms tailored for cell culture, including microcarrier-based suspension cultures X X
2 Immunotherapeutic technologies (allogenic and autologous), including universal T-cell, CAR-T, and dendritic cells X X
3
Cell processing and cell harvesting technologies for safe and effective harvesting of functional 
tissues, as well as organ banking and cryo-preservation of cells and tissues post-harvest; off-
the shelf CT products; bio- and cryo-preservation technologies enabling storage at room 
temperature X
4 Fill and finish technologies, including disposable manufacturing X
5
Technologies supporting Distribution, Logistics, and Clinical Administration, including hardware 
and software applications and processes to label, identify, and track products (from cells to 
product administration), and well as characterization of raw materials and enabling tracking 
back to raw materials X X X X
6
Technologies supporting standardization and automation, including moving to fully closed 
systems to ensure GMP and cGMP, in both the manufacturing and clinical environments; 
utilizing more digitization and controls connecting production to manufacturing, lab 
management, and QA systems X X
7
Technologies enabling quality control, including hardware, software, and data analytics to 
monitor (e.g. sensors for real-time monitoring) and collect critical process (CPP) data, as well 
as make real-time adjustments to processes parameters to ensure the production of materials 
expressing predetermined critical quality attributes (CQAs) X
8
Technologies enabling the development of 3D tissue constructs, including tissue engineering, 
biomaterials, and additive manufacturing technologies; improved resolution 3D 
printing/bioprinting, inks/printing materials for fabrication, automation, and integration in closed 
environments (for GMP and cGMP production) at manufacturing and clinical sites. X X X X
9 Stem cell therapies (allogenic and autologous), including MSCs and iPSCs, as well as therapies enabling control of stem cell differentiation and genetic mapping of stem cell behavior
 12 
 
 
Figure 5: Translational platforms that meet cross-cutting and co-investment criteria 
TRANSLATIONAL PLATFORMS FOR REGENERATIVE MEDICINE 
PLATFORM TECHNOLOGY: 3D CONSTRUCTS, INCLUDING ORGANOIDS, SCAFFOLDS, AND PRINTED TISSUES 
The key platform technology 3D Constructs, including Organoids, Scaffolds, and Printed 
Tissues was selected based on the potential for patient-specific applications. The development 
of constructs requires the integration of subfields such as tissue engineering, biomaterials, 
nanomaterials, and potentially, drug or biofactor delivery and genetic programming. The 
resulting three-dimensional structures can be used for the treatment of congenital conditions, 
and can treat tissue loss due to cancer or trauma.   
The pursuit of 3D constructs has clear value by enabling innovation in Regenerative Medicine to 
transition from bench to bed, from both the therapeutic and manufacturing perspectives. 
Ultimately, this will achieve the long-term goal of individualized medical care through the 
development of patient-specific, patient-tailored interventions including drug replacement with 
cell- or nanoparticle-based therapeutic and diagnostic agents and on-demand production of 
tissues, organs, and drugs. Within this context, scaffold technology, including smart scaffolds, 
de-cellularized scaffolds, designed scaffolds based on patient anatomical datasets, and 
combination devices comprised of scaffold-plus-biologics, is predicted to be a critical component 
of cell-based therapies for tissue- and organ-based regenerative approaches. Of special interest 
is the role these scaffolds play in matrix and stem cell niches for tissue and organ homeostasis 
and induced regeneration.  
In order to effectively realize the potential of 3D construct development, the Regenerative 
Medicine community will need to overcome a number of manufacturing and processing 
challenges:   
1. Limited understanding or control over cell complexity and self-assembly, both in vivo and ex 
vivo;  
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2. Inadequate understanding of the mechanisms for the recapitulation of signaling cues to 
induce regeneration; 
3. The need for improved biomaterials, bioinks and 3D printing systems to ensure improved 
resolution, fabrication, and good manufacturing practice (GMP) compliance, specifically as it 
applies to closed environments;  
4. The need for improved cell processing technologies, specifically for cell expansion, isolation, 
and separation; 
5. Limited supply and inconsistency of current cell culture media; and 
6. Current inability to control and standardize the process of blood vessel and nervous system 
innervation.  
While the development of fully functional organs may not be realized for several years, 
advancements in the development of novel structures can be demonstrated with an incremental 
approach, i.e., a step-wise development and validation of functional tissue and cellular 
components. In order to overcome biomanufacturing challenges, the Regenerative Medicine 
community (industry and government) should collaborate on: 
• Developing quality standards for materials, including drugs, biologicals, and cellular, 
nano-, and biomaterials,  
• Demonstrating self-assembly or self-assisted assembly of tissues and/or tissue 
components, and  
• Creating methodologies to address and advance media growth requirements, cell-matrix 
interactions, and ensure product sterility and stability, including preservation. 
Value Proposition: Advances in 3D constructs will lead to a better understanding of self-
assembly, as well as the ability to target cells or encourage vascularization in larger, thicker 3D 
constructs. Improvements in stability/sterility, and material processing in closed systems will 
ensure end products that not only demonstrate robustness over time, but also comply with 
current GMP standards. One area where 3D constructs may have an immediate impact is in 
providing advanced media for drug discovery and development research, enabling the use of 
partially developed, fully functional constructs or organoids for drug screening and toxicology 
studies. This approach offers reduced timelines and decreased costs of drug development. 
Keeping in mind the goal of enhanced biomanufacturing, it is important to note that “making” is 
not “manufacturing.” Advances in “making” technologies such as 3D printing in terms of 
resolution could make important (or significant) progress in developing functional 3D constructs. 
However, process technologies need to be matured for products to be manufactured in large 
quantities in order to serve the patient population. From the manufacturing perspective, 
consistency in product performance under varying conditions is a critical goal.  
PLATFORM TECHNOLOGY: BIOMANUFACTURING PROCESSES 
Given the inherent process management challenges encountered when manipulating cells and 
biological tissues, the development of stable, consistent and safe biomanufacturing processes is 
a key technology platform in Regenerative Medicine.  
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Because of the range of topics under the heading “Biomanufacturing Processes”, the area is 
further divided into two key enabling tools:   
(iii) Scaled-up bioreactors for cell culture, and  
(iv) Improvements in cell harvesting, cell processing, and preservation technologies; 
each directly affecting the supply of materials to the production process, and 
therefore requiring high-level management.  
Providing additional support for these enabling technologies will help to address the following 
technical challenges:  
1. Limited availability of suitable cellular materials and lack of consistency in material 
quality;  
2. Batch differences in raw biomaterials making process standardization difficult;  
3. Instability of cellular products resulting in loss of effectiveness, or robustness, of final 
product or materials on the production line; and  
4. Short product shelf life.   
Of special note is the development of effective room-temperature material stabilization. While 
this is a technically challenging problem, the successful deployment of Regenerative Medicine 
materials without the need for cryogenic storage would be transformative for delivering solutions 
in a clinical setting. 
Clear standards are paramount for both the manufacturing and the clinical environments.  
Ideally, standards should be set collaboratively between industry and regulators. 
 
ON THE HORIZON: HUMANIZED ORGANS 
Regenerative Medicine offers great hope for the future of health care – both by providing ex-vivo 
cells, tissues and even complete organs, and also by targeting the body’s own regenerative 
systems in developmental and immune molecular pathways. However, there is another approach 
that could also have a dramatic effect on the future manufacturing of human organs: organs could 
be grown in pigs for transplantation into humans. While a few, isolated attempts have been made, a 
major roadblock remains: porcine organs are not well tolerated by the human immune system since 
pigs contain more than 60 viruses imbedded in their own genomes which are a severe problem in 
immuno-compromised transplant patients. [a] CRISPR has now made it possible to remove all of the 
porcine viruses in a straightforward fashion. Immune genes could similarly be manipulated with 
CRISPR-like technology. Manufacturing of human organs in pigs could be a breakthrough 
analogous to auto manufacturing in the early 20th century, when Henry Ford created automated 
technology and the U.S. was able to supply a world-wide market. A consortium of government, 
industry, and academia could be a possible way to address the technical and IP challenges to 
large-scale humanized organ production.  
 
[a] Reardon, S. (2015) Gene-editing record smashed in pigs. Nature News. https://doi.org/10.1038/nature.2015.18525. 
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OTHER TECHNOLOGIES 
A number of other technologies were identified as potential platform solutions in Regenerative 
Medicine. However, these topics did not receive support from the majority of the Panel Experts 
during the poll.  
IMMUNOTHERAPEUTIC TECHNOLOGIES (ALLOGENIC AND AUTOLOGOUS) 
Immunotherapies are designed to control and regulate the immune system by targeting the 
inflammatory response, using the patient’s own cells to fight cancer, infection or other diseases. 
Regulation of the inflammatory process—the first target—coupled with better knowledge of 
inflammation mechanisms, could yield therapeutic interventions that may ultimately lead to more 
functional medical devices and human interface interaction. Significant challenges lie in the 
immune rejection of cell- and tissue-based therapeutic agents, but the recent success in 
creating universal blood 15  suggests the possibility of developing scalable manufacturing 
processes for allogenic products that can be used for a wide variety of patients. 
The other transformative platform technology, which targets a patient’s own cancer cells with 
engineered autologous T-cells, has the potential for developing therapeutic cures for many 
cancers. This platform technology capitalizes on developments in personalized cell therapy, 
gene therapy, and immunotherapy to result in activated chimeric antigen receptor (CAR) T-cells 
that seek out cancer cells. Early-stage trials with these CAR T-cells have been very successful 
and this has allowed therapies from this platform technology to undergo expedited regulatory 
review with the FDA. To date, there have been four IPOs of CAR T-cell focused start-ups. The 
next generation of CAR T-cell products is being developed to address safety concerns and the 
field has begun to focus on solid cancer tumors. 
Historically, the excitement and promise of this technology sector has been dominated by early 
successes of the cancer targeting CAR T-cell therapies. However, because CAR T-cell 
therapies have had a long history of development, this area is not suitable for further federal co-
investment to take this technology further. That role has been embraced by private investors in 
this space which has seen tremendous growth. Furthermore, regulatory hurdles have been 
significantly reduced, which is likely a testament to previous government investment to de-risk 
the technology. 
FILL AND FINISH TECHNOLOGIES, INCLUDING DISPOSABLE MANUFACTURING 
Fill and finish technologies are used in the final step of the pharmaceutical or biological 
manufacturing process. It is a step that does not entice innovation because doing so potentially 
introduces regulatory risk and cost to the process. However, packaging of cells or active 
biologics requires fill and finish technology innovation because traditional filling processes use 
elements that require sterilization. Single use technology completely eliminates the risk of 
contamination and infection and is a potential solution to the packaging problem of cells and 
                                                
15 Kwan, D.H., Constantinescu, I., Chapanian, R., et al. (2015) Toward Efficient Enzymes for the Generation of 
Universal Blood through Structure-Guided Directed Evolution. Journal of the American Chemical Society. 137(17), 
5695-5705. https://doi.org/10.1021/ja5116088. 
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biologics. Additionally, disposable technologies are very effective at minimizing the risk of cross 
contamination.   
As with current medicine, application of disposable fill and finish technology for Regenerative 
Medicine applications has the same goal of zero contamination, but will require an innovative 
design of the manufacturing process when dealing with cell-based elements. Successful fill and 
finish solutions in Regenerative Medicine will impart stability (especially protein stability), ensure 
sterility and increase product lifespan.  
Fill and finish technologies for biologics are a mature technology and therefore the technology is 
not considered to be suitable for investment by the government because many private 
companies are already active in this area.  
STEM CELL THERAPIES (ALLOGENIC AND AUTOLOGOUS)  
Stem cell therapies hold tremendous promise for eventual therapeutic interventions that can 
offer full recovery of lost tissue function and return patients to a satisfactory quality of life. From 
the perspective of the initial selection criteria, stem cell therapies are high in co-investment 
potential (as shown by government initiatives in California, 16  Canada, 17  and the UK 18 ). 
Furthermore, the technology readiness of this group of therapies falls squarely within the 
targeted TRL 4-7 range.  
One stem cell lineage with particular promise is based on induced pluripotent stem cells, or 
iPSCs. In the most basic terms, iPSCs impart the ability to transform committed differentiated 
somatic cells into pluripotent stem cells, capable of the functionality inherent to “natural” stem 
cells. When combined with other RM translational technologies such as 3D bioprinting, iPSCs 
could allow for the on-demand production of patient-specific tissues and organs. Looking to the 
future, the generation of whole organs populated by patient iPSCs could alleviate the donor 
organ shortage, and prove transformational for end-stage organ failure patients. Fundamental to 
the successful commercialization of iPSC therapies, then, will be the ability to generate in high 
volume, robust and consistent high-quality “living” products comparable across multiple lines. To 
do so, key manufacturing and engineering processing challenges need to be addressed.   
Currently, there are several methodologies in use to reprogram somatic cells for the eventual 
creation of iPSCs. As such, there exists significant variability in source materials and 
processing, both potentially translating to significant variability in the iPSC end product. Since 
iPSCs are not the focus-product for RM therapies (differentiated target cell types are), the 
variability in processing required to generate comparably committed cell types may also be 
affected. The consistency of cell products across different sources is a substantial challenge, 
especially considering a patient’s genetic heterogeneity, disease heterogeneity, as well as the 
need to create large repositories of iPSCs. 
To circumvent many of these challenges, stricter standards will need to be enforced at the 
manufacturing stage than those applied at the laboratory-level for standardized methodologies 
                                                
16 California Institute for Regenerative Medicine, https://www.cirm.ca.gov/.  
17 Canadian Stem Cell Foundation, http://stemcellfoundation.ca/en/.  
18 UK Stem Cell Foundation, http://www.ukscf.org/.  
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and processes for iPSC production, differentiation, and maturation. Potential production vehicles 
include bioreactors, or the use of a platform cell such as patient-derived fibroblasts. 19 
Additionally, there is a need to acquire knowledge of critical quality attributes and the processing 
parameters for pheno- and geno-typically stable products. 
The decision to not add stem cell-based therapies to the current list of priorities was based, in 
part, on the recognition that successful commercial translation will also depend on harmony 
within the regulatory landscape and attitudes toward clinical adoption. Both areas underpin 
clinical administration and, ultimately rely on the availability of much needed safety and efficacy 
data obtained through clinical trials. 
 
BROADER CHALLENGES AND THE ROLE OF THE FEDERAL GOVERNMENT 
REGULATORY PROCESSES FOR REGENERATIVE MEDICINE 
Because of the unique regulatory challenges in Regenerative Medicine, a group of nationally 
recognized experts with direct experience in healthcare regulations was asked to comment on 
how regulations can be adapted to this field. (See Table 2.) Additional experts were consulted 
informally.   
1: Regulatory mechanisms for Regenerative Medicine that ensure safety, efficacy and 
security  
Regulatory mechanisms such as orphan drug designation and expedited review are designed to 
make drugs available to patients more quickly. While these current mechanisms are important 
                                                
19 To date, the ideal starting cell for iPSC products has not been determined. 
ON THE HORIZON: USE OF EX-VIVO ORGANS FOR SCREENING EXPERIMENTAL DRUGS 
While the delivery of whole organ creation remains in the distant future, there are two offshoots of 
this technology that could, in the near term, dramatically affect the development/risk model for the 
production of pharmaceuticals.   
1) Partially developed but functional, ex-vivo organs (or parts thereof) could be used to screen drug 
candidates for toxicological and other side effects much earlier than human clinical trials. This 
process has the potential to reduce the use of expensive human clinical trials in the drug 
development process.   
2) Tissue systems or organoids built from human clinical trial progenitor cells with encoded various 
disease states could be used to more effectively screen drugs early in the pipeline and thus greatly 
increase the effectiveness of matching drug candidates with their targets. This could lead to 
significant upfront cost savings by reducing the amount of developmental working capital and by 
reducing the risks of the upfront pharmaceutical R&D model.   
Both items could potentially improve the drug manufacturing process dramatically in the 
short/medium range. Ex-vivo drug screening offers the tantalizing option of identifying organ-specific 
toxicities much earlier than current screening methods. 
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pathways to accelerate drug development, there is support in industry for an accelerated 
regulatory pathway specifically designed for regenerative medicine.   
For example, a significant challenge for the young field of cell therapy product development is to 
create and optimize manufacturing processes while the technologies themselves are quickly 
evolving. In particular, there is not a specific regulatory mechanism currently available to help 
streamline continuous process improvement. Nor is there a mechanism to guide the gradual 
optimization of that process as new technologies become available. Instead, what constitutes a 
minor versus major process improvement is not clear to the product developer. Industry finds it 
challenging to understand what triggers the need for a formal comparability exercise vs. 
continuous process improvement.  
Ideally, a more flexible regulatory mechanism in the cell therapy space would exist for 
continuous process development. This concept follows the spirit of the adaptive licensing20 
approach, which is an iterative process of gathering evidence of potential therapeutic indications 
followed by progressive licensing adaptations. 
A more flexible regulatory approach would improve upon the current status, where the 
accelerated clinical development (made possible by existing expedited regulatory pathways) 
places even more pressure on the need for process development to align with accelerated 
clinical development timelines, and potentially support earlier product marketing.  
It would also be beneficial if Regulators were more liberal on how existing pathways could be 
used for new products. For example, conditional approval could be granted using a limited data 
set based on the assurance that more robust data would be provided at a later date.   
2: Structure of the FDA’s Centers  
The FDA centers, offices, and divisions who currently have the oversight in this space are, in 
general, appropriate for the current technologies being developed. In particular, the Office of 
Combination Products (OCP) coordinates activities of several centers within the FDA. The OCP 
makes formal determinations on Center jurisdiction (e.g., biologic to be reviewed by CBER) and 
also coordinates cross-Center collaborative and consultative reviews. In the case of a sponsor 
of a biologic-device cell-based combination product, which is also an HCT/P, that sponsor will 
have to consider cGMP regulations for drugs (21 CFR 210 and 211), any applicable regulations 
not already addressed for the biologic component (21 CFR 600 to 680), the remaining 
applicable regulations not already addressed for device component in the QSRs (21 CFR 820), 
and the remaining applicable regulations not already addressed, given that the biologic 
component is an HCT/P, in the cGTP regulations (21 CFR 1271).  
There are numerous regulations to follow and rules in place to avoid unnecessary duplication in 
regulatory oversights. It is not clear how/if a new Center or other mechanism would streamline 
this any further based on current regulations.  
                                                
20 Adaptive Licensing can be defined as a prospectively planned, adaptive approach to bringing drugs to market.  
Adaptive licensing seeks to balance the desire to deliver new drugs to the public with the need to provide adequate 
information on potential benefits and possible harm. See 
http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2015/11/WC500196323.pdf.  
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As the development of complex biologics progresses, the need for a more flexible pathway to 
market also increases. The Panel Experts suggested that Regulators should consider 
processes that recognize this fact.  
3: Engaging the public and establishing priority topics 
As the regulatory stakeholders consider processes to correct possible regulatory misalignments, 
public workshops can be used to identify priority topics so that the public can be included in the 
process of developing solutions. Such workshops should address specific regulatory 
considerations for new products, potential pathways for approval of personalized medicine, etc. 
An important question is how the regulatory process can be navigated when the product is not 
exactly like the product types described in the regulations. However, the issue is not simply a 
case of misaligned regulations, but rather a need for more specific regulatory considerations 
and requirements that can be further evaluated. The previous discussion on continuous process 
development under Item 1 is a good example. While this question may be addressed via new 
regulations, a more efficient method would be through regulatory policy and Guidance 
Document development, as well as the utilization of standards in the regulatory review process. 
Furthermore, there is room for additional guidance regarding comparability of manufacturing 
products either due to changes in process or donor variability. Of course, any changes to the 
regulatory requirements should also maintain the same levels of safety that are currently 
employed by the FDA and evidence of efficacy. 
A related issue is the considerations necessary for the approval of technologies in personalized 
medicine. The current approval considerations for clinical efficacy are based on population 
effect with statistical power. However, for autologous products, a key question stands out: Is it 
still appropriate to measure clinical efficacy based on statistically meaningful population effects 
of an investigational drug/product when cell products, manufacturing process of each product, 
and treatment effects are so individualized? The answer lies in the identification of the 
appropriate methodology to evaluate clinical efficacy/treatment effect, irrespective of 
comparability. 
4: Developing industry consensus on acceptable standards 
A number of efforts by industry are underway to set standards. 
The Alliance for Regenerative Medicine (ARM) has initiated the establishment of a Standards 
Coordinating Body, or SCB, for Cellular/Gene and Regenerative Therapies. The SCB is being 
established in order to: organize all stakeholders, and coordinate activities in identifying gaps 
and needs in standards, contribute to developing standards (including within existing consensus 
standards development organizations, where some standards are intended to help streamline 
regulatory review), and finally, to disseminate and implement standards once developed. The 
Cellular/Gene and Regenerative Therapies SCB can serve as the common voice.  
In addition, organizations such as the IABS21 have examined areas where there is a need to 
develop tools or approaches. As an example, see “Extent and Content of Data for Regulatory 
                                                
21 International Alliance for Biological Standardization (IABS), www.iabs.org.  
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Submissions: First-in-human and Marketing Authorization - Viewpoint from US Industry” by 
Harris.22 
The ICH23 may also play a role in regulatory convergence, and potentially standards, for testing 
donors, manufacturing intermediates and final product. Additional organizations that represent 
stakeholders include the ISCT24 and the ASGCT25 that have established standards in the past.    
The question of “acceptable liability, or what creates customer satisfaction” will have to be 
established within each of the established therapeutic areas. Examples of such organizations 
include the American Heart Association or American College of Cardiology for Regenerative 
Medicine products used for cardiovascular disease. 
Overall, the FDA is encouraged to recognize consensus standards developed via structured 
processes put in place by all the stakeholders, such as through ISO26 and ASTM27.  
SUMMARY 
The comments from the regulatory experts can be distilled to three main points:   
o There are a range of comprehensive regulations in place with FDA Centers and 
Divisions to regulate the regenerative medicine space; 
o More flexible regulatory mechanisms will help accelerate Cellular/Gene and 
Regenerative Therapy product development, particularly manufacturing process 
development; 
o Developing standards is important, and several organizations have initiated such efforts, 
such Standards Coordinating Body, IABS, etc. The recognition of consensus standards 
(e.g. ISO and ASTM-developed) by FDA CBER to be utilized in the regulatory review 
process would be beneficial. 
Regulatory Experts for Regenerative Medicine 
Name Title Affiliation 
Jiwen Zhang, Ph.D.    Senior Regulatory Affairs Director, Co-chair 
ARM S&T Committee 
GE Healthcare (GEHC) 
Ian Harris, Ph.D. Senior Director, Cell Therapy Janssen R&D LLC 
Michael Mendicino, Ph.D. Regulatory Affairs Director, Co-chair ARM 
S&T Committee 
Mesoblast 
                                                
22  Harris, I. R. (2015). Extent and Content of Data for Regulatory Submissions: First-in-human and Marketing 
Authorization - Viewpoint from US Industry. Biologicals, 43(5), 402–405.  
23 International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), 
www.ich.org. 
24 International Society for Cellular Therapy, http://www.celltherapysociety.org/. 
25 American Society of Gene & Cell Therapy, http://www.asgct.org/. 
26 International Organization for Standardization, www.iso.org. 
27 ASTM International, www.astm.org. 
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Anthony Ting, Ph.D. Vice-President, Regenerative Medicine & 
Head of Cardiopulmonary Programs 
Athersys, Inc. 
Table 2: List of regulatory experts in Regenerative Medicine 
INVESTMENT METRICS 
As with most emerging industries, early-stage technology development in Regenerative 
Medicine has a high risk profile. Consequently, the potential for return on RM investment (ROI) 
is largely unclear. It was indicated that sympathetic changes in the regulatory environment 
would certainly improve the time to market. Beyond that, investment barriers could be lowered 
with 1) improved understanding clinical applications and outcomes; 2) investable milestones; 3) 
intellectual property protection; 4) presence of competing products (which show the potential for 
revenue); and 5) a clear understanding of reimbursement requirements and the ability to 
manufacture at reimbursable costs. These measures will achieve much in terms of de-risking 
technology and encouraging investment. 
INVESTMENT BARRIERS 
For larger companies (aka, “big pharma”), excess risk represents a substantial barrier to 
investment. Without the investment participation of larger companies in Regenerative Medicine, 
smaller companies face even larger hurdles to secure funding. Larger entities need to step in 
with financial support so that many of the revolutionary platforms under development can reach 
the required level of maturity for the market. At the current time, private funding is inadequate 
for further development of translational platforms on larger scales and the need for regulatory 
filings and clinical studies.  
Investment is also hindered by long development times resulting from regulatory requirements. 
Regulators typically require large amounts of efficiency and comparability data (often difficult to 
produce) and this results in exceedingly long times to market approval and an added risk of 
being obsolete by the time the product is approved.  
Additionally, the clinical utility of the technology must be clearly and tangibly identifiable. 
Investment should be directed towards developing technologies for commercialization and also 
into areas that require capital investment for proof of concept, largescale implementation, 
regulatory filings, and clinical studies. Moreover, private sector investment is likely to increase if 
regulatory clarity and pricing support from payers and government can be made more clear and 
transparent. 
Other barriers-to-investment include: 
i) Poor numbers of therapeutically active products—either coming to or currently on the 
market;  
ii) Poor, or not well-understood “clinical fit”; 
iii) Problems with bio-preservation; and  
iv) An inadequate understanding of workflow and logistics.   
There is also a need for new business models for profits—especially with regards to cell 
therapies—and an understanding of what can be mass-produced. 
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ROLE OF FEDERAL GOVERNMENT 
The technology development process can be de-risked through government support in several 
ways, including reducing the regulatory burden and providing clear licensing paths. However, 
the caveat to government investment should be focused on pre-competitive biomanufacturing 
tools that are openly accessible across the industry.  
Investment of taxpayer dollars in new therapies can be justified by demonstrating that a change 
in standard care will offset the largely wasteful spending on antiquated systems and treatments 
currently in place.   
Justifications for investing taxpayers’ dollars include: 
i) The creation of a strong infrastructure for continuous growth of the industry;  
ii) The elevation of spin-off companies into viable commercial companies;   
iii) The development of ecosystems to facilitate interdisciplinary collaboration and 
commercialization; 
iv) An improvement in the standard of care that will lead to reduced healthcare costs, as 
well as the delivery of scalable products to market that address unmet medical needs. 
In addition to providing targeted funding, the Federal Government has a vital role in facilitating 
partnerships, including government-industry or industry-academia. Any collaborative partnership 
needs to have well-defined steps and options for managing attrition, and should focus on a 
recognized model for translation and commercialization. 
Finally, the Federal Government has a uniquely important role in disseminating science-based 
data on cutting-edge Regenerative Medicine technology. Funding often slows or is cut for 
certain technologies where misinformation from opponents has engendered negative public 
sentiment. Consistent, reliable publication of objective, science-based data will contribute to a 
robust discussion on Regenerative Medicine topics. New technologies such as CAR-T therapy28 
are particularly prone to public debate that might slow down the pace of development. 
TECHNOLOGY TRANSFER 
There are a number of barriers to transferring technology from academia to the marketplace. 
First, many university technology transfer offices do not understand the complexities of maturing 
a technology into a market-ready state, often causing an overvaluation of early-stage 
discoveries. The academic community is typically unfamiliar with the amount of non-clinical 
testing and manufacturing that is necessary to transition a product from proof-of-concept in the 
lab to exploratory clinical research. Bringing a product to market is a multi-step process 
involving regulatory issues, marketing strategies and (ultimately) operation, especially within the 
GMP regime. University technology transfer offices often lack the seasoned staff and 
experience to correctly account for these development factors.    
                                                
28 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Leukemia & Lymphoma Society,  
https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy  
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Second, federal funding for basic science will typically not fund work when it moves into the 
development stage. This often leaves a major gap in support at a critical time in the process. 
Some options such as SBIR/STTR exist to continue development work, but the relative funding 
level for this program is much smaller than is needed to make any real progress.  
PARTNERSHIPS 
In most cases, partnerships are critical for the transition of early-stage studies (done at the 
startup level) to more mature technologies. As an example, the development of new cell 
therapies has typically involved a partnership between larger companies (pharmaceutical 
conglomerates or international players) and small startups. This model results in a nimble 
development capability as well as the means and networks necessary to reach a global 
audience. 
In general, successful strategic partnerships will combine entities with complementary 
capabilities across the spectrum of development to commercialization. In the realm of 
therapeutic development, partnerships should include three basic capabilities: research, 
application and translational development, and full development/commercialization. 
For those research institutions working with early-stage technologies, the ideal partnership 
would include a relationship with an entity that has strong translational capabilities. Specific 
examples include:   
• A biotechnology company with relevant domain expertise and capabilities that extend from 
research and application through proof-of-concept (POC) development and often into later 
clinical development and commercialization. It could involve federal funding (NIH, DOD, 
NSF, etc.).   
• A translational group within a larger pharmaceutical company (e.g., NIBR in Novartis29). 
These entities provide the expertise to carry through to proof of concept, and often have 
defined channels for further collaboration, partnership, and advancement for late 
development and commercialization.   
• Specialized entities and not-for-profit organizations, which can play the role of converting lab 
technologies with promise into verified development candidates. Examples include The 
Harrington Project / Biomotiv30 and others.   
An optimal partnership arrangement successfully aligns the level of co-investment with the risk 
absorbed by each party in the partnership at that level. For public/private partnerships, funding 
for the partnership could take a number of forms: 
                                                
29 Novartis Institutes for Biomedical Research, https://www.nibr.com/. 
30  The Harrington Project is a novel tripartite collaboration between non-profit and for-profit organizations. The 
Harrington Discovery Institute provides financial and non-financial support to physicians-scientists working on 
targeted translational research. The Innovation Support Center provides additional financial support coupled with 
drug development infrastructure to further mature translational research. Late-stage commercialization partners are 
matched with academic project through BioMotiv, a mission aligned commercial development company. See: 
http://www.uhhospitals.org/services/harrington-discovery-institute/about/harrington-project-for-discovery-and-
development  
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• The private entity could receive a direct grant by the public entity for participation; 
• The public entity could supply a reimbursable contribution against the private partner’s 
project costs; or  
• The government entity could supply a simple tax offset to the private partner. 
Another partnership possibility is an innovative clearinghouse concept, designed to bundle 
multi-component technologies. Financing would be enabled with an access fee to gain visibility, 
a pre-negotiated technology evaluation pathway, and preferred partner status allowing for rights 
of refusal elements. 
The Federal Government can look to a number of existing structures that currently exist to 
transition basic research into more commercially viable technology. These include: 
• Company-to-institution partnerships , e.g., GSK / Harvard and stem cells;31  
• Consortia, such as CRC-CTM32 in Australia, CSCRM33 in Cleveland, CCRM34 in Canada;  
• Groups or foundations that fund or support translation or POC work, e.g., CIRM35 (funding), 
Catapult (capabilities/expertise), the foundations (Cystic Fibrosis, Multiple Sclerosis, etc.); 
• Government collaborations, such as,  
o SBIR/STTR program with specific RFA for Regenerative Medicine studies (U.S.) 
o Innovate UK36 and Cell and Gene Therapy Catapult37 (UK) 
o CCRM (Canada) 
o NHLBI-CCTRN38 
Typically, public-private partnerships are most successful when publically-invested technology is 
“packaged for sale” to interested commercial parties. The technology package should clearly 
identify possible applications areas, technology readiness level (TRL) status, and estimated 
investment to complete development. The key issues of IP protection and freedom to operate 
(preliminary) should be sorted out a priori.  
                                                
31 Colen, B. D. (2008). “GlaxoSmithKline and Harvard Stem Cell Institute announce major collaboration agreement.” 
Harvard Stem Cell Institute. http://news.harvard.edu/gazette/story/2008/07/glaxosmithkline-and-harvard-stem-cell-
institute-announce-major-collaboration-agreement/. 
32 CRC for Cell Therapy Manufacturing (CRC-CTM), http://www.ctmcrc.com/. 
33 Center for Stem Cell and Regenerative Medicine (CSCRM), https://www.bioohio.com/item/center-for-stem-cell-and-
regenerative-medicine-cscrm/. 
34 Centre for Commercialization of Regenerative Medicine (CCRM), http://ccrm.ca/. 
35 California Institute for Regenerative Medicine (CIRM), https://www.cirm.ca.gov/. 
36 Innovate UK, https://www.gov.uk/government/organisations/innovate-uk.  
37 Cell and Gene Therapy Catapult, https://ct.catapult.org.uk/.  
38 National Heart, Lung, and Blood Institute (NHLBI), http://www.nhlbi.nih.gov/, and Cardiovascular Cell Therapy 
Research Network (CCTRN), https://ccct.sph.uth.tmc.edu/cctrn/. 
 25 
 
INTERNATIONAL BENCHMARKING 
The U.S. is a leader in scientific discovery due primarily to its large concentration of academic 
research and high numbers of spin-off startup companies in the Regenerative Medicine space. 
Furthermore, the U.S. business environment can attract the required highly-skilled researchers 
needed to work in startup companies, and also in larger more established firms. Several experts 
commented on the positive effect of government support of partnerships between industry and 
academia. One positive feature of government involvement is that that risk-tolerant venture 
capital firms are more likely to fund early stage development work when the government 
supplies both partial funding and an organizational structure for academic and private entities. A 
key advantage is the domestic development and infrastructure for key technologies such as 
artificial cellular systems (electrospinning and bioprinting), genetic-engineering-based 
technologies (liposome encapsulation and CRISPR), and organ-banking and next generation 
biopreservation.  
The U.S. does, however, have substantial disadvantages compared to other countries. These 
include a lack of focus on process engineering, manufacturing, and clinical trials, leading to 
serious obstacles to commercialization. Disadvantages were identified associated with less-
supportive regulatory, tax, and healthcare infrastructures and increased legal barriers. Public 
acceptance/reluctance on topics such as the use of human embryonic stem cells (hESCs) have 
led to uncertain (and erratic) funding, which is a huge disadvantage for technologies that may 
require as much as a decade to commercialize. 
Also, because the U.S. healthcare system does not support universal healthcare, it is difficult to 
move innovation towards cost-effective solutions since reimbursement for such services 
remains unclear. 
Several countries outside of the U.S. are very successful in the area of commercialization 
because they have established innovation centers that incorporate process engineering and 
manufacturing from idea inception through prototype development; from clinical trial, to nurturing 
and supporting spin-off companies. 
SUMMARY 
The objective of this report was to identify translational platform technologies with crosscutting 
appeal in Biomanufacturing for Regenerative Medicine that warrant investments in translational 
research through public-private partnerships. Several challenges and opportunities were 
identified across therapeutic platforms and manufacturing platforms. Topics that gained most 
support with crosscutting appeal and possess the correct maturity level to warrant co-
investment by private industry were: 
i) 3D constructs including organoids, scaffolds, and printed tissues. Advances in these 
technologies will have cross-cutting applications including development of partial or 
fully functional tissues/organs, as well as tools for predictive modeling and drug 
screening. 
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ii) Biomanufacturing process technologies that enable therapeutic platforms to 
transition from bench to bed, including bio-reactor scale-ups and tools for 
processing, harvesting, and preserving cells.  
In addition to technology development, there is a need for science-based regulation, public 
acceptance, and the development of standards.  
ADDITIONAL REPORTS 
Many of the ideas and suggestions presented in this report are congruent with those of other 
recently published reports. A report by the Cell Manufacturing Consortium (CMC) 39  also 
recommended and prioritized, in a similar fashion, translational technologies and platforms, 
highlighting current and on-the-horizon applications of cell-based therapies. The CMC report 
concluded that the development of cell processing technologies, (as well as of several enabling 
technologies – supply chain, quality control, and preservation – for example) are on the critical 
path to successful scale-up or scale-out. This report independently arrived at similar 
conclusions. 
This report’s findings are also echoed in the World Technology Evaluation Center report40 that 
evaluated RM technology transfer in Europe and Asia, and asserted that the seemingly 
insurmountable barriers to the widespread implementation of technological innovations in 
Regenerative Medicine may be overcome through cooperative collaboration and 
interdisciplinary work.  
Both reports also emphasize the need for sustained focus on improvements in process 
engineering as especially key for the practical application of biomanufacturing for cell therapies, 
as well as the need to apply known principles early in the product conceptualization process. 
 
 
                                                
39 “Achieving Large-Scale, Cost-Effective Manufacturing of High Quality Cells:  A Technology Roadmap to 2025.” 
Georgia Research Alliance and Georgia Institute of Technology. December 2015. 
40 “Global Assessment of Biological Engineering & Manufacturing.” World Technology Evaluation Center (WTEC). 
July 2015. http://www.wtec.org/bem/docs/BEM-FinalReport-Web.pdf.  
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PANEL EXPERTS 
This report would not have been possible without the enthusiastic and dedicated participation by 
the national thought leaders on our Regenerative Medicine Panel Experts. During the course of 
the effort, the authors had the pleasure of personal communications with each Panel Expert, 
receiving valuable information on the topic. Whether by email or phone, each and every request 
was answered promptly and completely. The authors gratefully acknowledge their participation 
in the creation of this report. 
 
Panel Experts for Regenerative Medicine 
Name Title Affiliation 
Eytan Abraham, Ph.D. Head of Cell Therapy Research and 
Technology 
Lonza Walkersville Inc. 
Tim Bertram, Ph.D., DVM CEO and General Director RegenMed Therapeutics 
Ian Harris, Ph.D. Senior Director, Cell Therapy Janssen Research & 
Development, LLC 
Sandro Matosevic, Ph.D.41 Director of R&D Akron Biotechnology 
Anthony Ting, Ph.D. Vice-President, Regenerative 
Medicine 
Athersys, Inc. 
Phil Vanek, Ph.D.42 General Manager, Cell Therapy 
Technologies 
GE Healthcare (GEHC) 
Kaiming Ye, Ph.D. Professor and Department Chair Binghamton University, State 
University of New York (SUNY) 
Jiwen Zhang, Ph.D.42    Senior Regulatory Affairs Director GE Healthcare (GEHC) 
Claudia Zylberberg, Ph.D.41 Chief Executive Officer Akron Biotechnology 
 
EYTAN ABRAHAM 
Dr. Eytan Abraham heads up the Cell Therapy Research & Technology (R&T) group at 
Lonza, Inc. in Walkersville, MD. Dr. Abraham’s R&T group develops and tests enabling 
technologies and methods to facilitate large scale cell therapy manufacturing for 
allogeneic and autologous clinical trials and commercial use. One major R&T initiative is 
the use of bioreactor platforms to produce large numbers of various cell types to meet 
cell therapy commercialization need; while maintaining high-cell quality and reducing 
costs. Previously Dr. Abraham was the Head of Product Innovation at Pluristem 
Therapeutics. This group developed a pipeline of MSC therapies tailored for different 
clinical indication, by altering various aspects of the 3-D bioreactor culture environment.   
                                                
41 Drs. Matosevic and Zylberberg (Akron Biotechnology) collaborated to submit a common response.  
42 Drs. Vanek and Zhang (GE Healthcare) collaborated to submit a common response. 
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Dr. Abraham holds a Ph.D. in developmental biology from the University of Maryland 
Biotechnology Institute and conducted his post-doctoral training on tissue engineering 
and cell therapy at the Harvard-MIT Biomedical Engineering Center (HST) and Harvard 
Medical School. 
TIM BERTRAM 
Tim Bertram is the CEO and General Director of RegenMed Therapeutics, a clinical-
stage biotechnology company focusing on a breakthrough cell-therapy to delay or 
prevent renal transplantation / dialysis. Past experiences include President Research & 
Development and Chief Science Officer for Tengion, a tissue engineering and cell 
therapy development company, and various senior executive positions in the 
pharmaceutical industry including Pfizer, SmithKline Beecham Pharmaceuticals, and 
Procter & Gamble Co.  
Post academic experiences included time as an invited scientist to the National Institutes 
of Health, faculty member at University of Illinois, and faculty advisor to academic 
institutions in the U.S. and Europe for research and training program development. 
Multiple patents and peer reviewed publications relating to cellular therapeutic and tissue 
engineered product development. He has established 4 commercial-scale development 
acquisitions/partnerships bringing regenerative medical technologies into the regulatory 
development paradigm in the U.S. and Europe, and was involved in the registration and 
commercialization of 8 medical products currently on the market.  
IAN HARRIS 
Ian Harris is the Product Development Team Leader for CNTO 2476, which is the lead 
allogeneic cell therapy product for geographic atrophy secondary to age related macular 
degeneration and is responsible for manufacturing development, mechanism of action 
aspects of the CNTO 2476 program. Ian joined the Johnson & Johnson (J&J) family of 
companies in 2000 and has held various positions of increasing responsibility within the 
area of cell-based therapeutics. Prior to joining J&J, Ian was a laboratory leader at 
Beiersdorf in Hamburg, Germany, developing skin care products.  
Ian has a Ph.D. in biochemistry and molecular biology from University of Leeds, UK 
where he studied wound healing and developed cell therapies for treating venous leg 
ulcers and burns.  
SANDRO MATOSEVIC 
Sandro Matosevic, Ph.D., is Director of R&D at Akron Biotechnology, LLC, a company 
that develops, manufactures and markets bio-tools and high-end cell culture products 
under cGMP for the Regenerative Medicine industry. Dr. Matosevic is responsible for the 
discovery and development of a range of novel cell therapy products and technologies: 
from recombinant proteins to cryopreservation media. His expertise is focused on the 
areas of bioengineering, microfluidics, liposomal delivery systems, recombinant protein 
production, novel cryopreservation media, synthetic biology and stem cell and tissue 
engineering. Dr. Matosevic also holds a position on the Communication committee at the 
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International Society for Cellular Therapy, and is adjunct professor at the Department of 
Biotechnology at Palm Beach State College. 
Dr. Matosevic holds a Ph.D. in Biochemical Engineering from University College London. 
He carried out his postdoctoral training at Department of Chemistry at The Scripps 
Research Institute. 
ANTHONY TING 
Dr. Ting is Vice President of Regenerative Medicine and Head of Cardiopulmonary 
Programs at Athersys, Inc. With more than 25 years of experience in cell and stem cell 
biology, he has been a key leader in the Regenerative Medicine division at Athersys for 
the past 14 years. He has both clinical and scientific expertise with the translation of 
adult stem cell therapies and has been responsible for all development stages of 
bringing MultiStem, an allogeneic adult stem cell, from the bench to the bed. Currently, 
he is the PI on an NHLBI-funded Phase II clinical trial for AMI with MultiStem and the 
project lead for a TSB-funded Phase I/II clinical trial for ARDS with MultiStem. Prior to 
joining Athersys, Dr. Ting was a Principal Investigator at the Institute of Molecular and 
Cell Biology at the National University of Singapore where he established a drug 
discovery program.   
Dr. Ting received his B.A. from Amherst College, a Ph.D. in Cell Biology from Johns 
Hopkins University and conducted his post-doctoral training in Molecular and Cellular 
Neurobiology at Stanford University. 
PHIL VANEK 
Phil is General Manager of GE Healthcare’s Cell Therapy Technologies business, a 
business initiative funded in part by GE Healthymagination, a $6 billion strategy to 
revolutionize the world’s health by improving the quality, access and affordability of care. 
Prior to joining GE, Phil was Head of Innovation for Lonza’s Pharmaceutical division. 
Phil’s career has included a number of senior innovation, business and market 
development roles at Becton Dickinson, Invitrogen, and Life Technologies, as well as 
two start-up biotechnology companies in the Washington, DC area. Phil is an active 
member of the Alliance for Regenerative Medicine, where he currently serves as an 
Officer of the Executive Committee. Phil has also been recently elected to the Centre of 
Commercialization of Regenerative Medicine (CCRM) Board of Directors in Toronto, 
Canada, and serves on the Editorial Board of Cell and Gene Therapy Insights. 
Phil received his Ph.D. in Biochemistry and Molecular Biology from Georgetown 
University Medical Center and subsequently held an IRTA fellowship at the National 
Cancer Institute in the Laboratory of Molecular Oncology.  
KAIMING YE 
Dr. Kaiming Ye is a Professor and Department Chair of Biomedical Engineering at the 
Binghamton University, State University of New York (SUNY). He was Program Director 
at NSF before joining Binghamton University. He is one of the most accomplished 
leaders in the field of Medical and Biological Engineering. He is Fellow of the American 
Institute of Medical and Biological Engineering (AIMBE) and Senior Member of IEEE. 
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During his tenure at NSF, he managed neuroscience and cell biomechanics funding 
program and was member of a number of interagency working groups including 
Interagency Working Group for Neuroscience under the Office of Science and 
Technology Policy (OSTP), Multiagency Working Group for Tissue Engineering and 
Regenerative Medicine and DARPA Government Oversight Committee. His research 
interests include 3D bioprinting, advanced biomanufacturing, stem cell engineering, 
regenerative medicine, imaging and vaccine development. He is best known for his 
creative works in 3D differentiation of human pluripotent stem cells into clinically relevant 
cell lineages and development of fluorescent nanosensors for continuous glucose 
monitoring. His research has been continuously supported by NIH, NSF, JDRF, ABI and 
industry funding. He has chaired and co-chaired a number of international conferences 
and has been invited to deliver keynote/plenary speeches in numerous international and 
national conferences. He serves as Editor-in-Chief, Executive Editor, Associate Editor, 
and member of Editorial Boards of 13 journals.  
JIWEN ZHANG 
Dr. Jiwen Zhang is a Senior Regulatory Affairs Director at GE Healthcare (GEHC), 
leading regulatory strategy development for Cell Technology and Biotechnology. Before 
joining GEHC, she had worked in the pharmaceutical industry at companies including 
Centocor/Johnson & Johnson, Merck & Co., Wyeth Pharmaceuticals, and Sanofi-
Aventis, where she led regulatory strategy development for both marketed products and 
development compounds in multiple therapeutic areas. She is currently leading various 
industry initiatives through Alliance for Regenerative Medicine, International Society for 
Stem Cell Research, ILSI Health and Environmental Sciences Institute, and International 
Standards Organization (ISO). She is on the steering committee for the FDA/CDER 
CiPA initiative (Comprehensive in vitro Proarrhythmia Assay), and co-chairing the 
human stem cell derived cardiomyocyte work stream. 
Dr. Zhang obtained her Bachelor of Science degree in Biology from University of 
Science and Technology of China and her Ph.D. in Neuroscience from the joint 
Physiology and Neurobiology program at Rutgers University and University of Medicine 
and Dentistry of New Jersey. 
CLAUDIA ZYLBERBERG 
 Claudia Zylberberg, Ph.D., serves as Founder and Chief Executive Officer and 
President of Akron Biotechnology, LLC, a company that develops, manufactures and 
markets bio-tools and high-end cell culture products under cGMP for the Regenerative 
Medicine industry. Dr. Zylberberg co-founded Akron Clinical, today CTIFacts Latam a 
clinical CRO specializing in cell therapy clinical trials in Latin America. She also co-
founded AssureImmune, a family stem cell bank that engages in R&D of cell therapies 
for the use of adult stem cell. Dr. Zylberberg is affiliated with the International Society for 
Cell Therapy (ISCT) and holds many nonexecutive positions: Board Member and 
Scientific Advisor, Alliance for Regenerative Medicine (ARM); Board Member, 
BioFlorida; Board Member, Palm Beach State College; and Chair of Industry Advisory 
Board, West Palm Beach, Florida. 
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Dr. Zylberberg holds a Ph.D. in Biotechnology from the University of British Columbia 
and University of Buenos Aires and has over 30 years of experience in the international 
biopharmaceutical industry. Her expertise is focused on the areas of recombinant protein 
production, human-derived blood products, stem cell banking and new cryopreservation 
media. 
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APPENDIX 1: INITIAL PROJECT GUIDANCE & RESOURCES 
QUESTIONS 
1. Advanced	manufacturing	technologies/processes	
a. For	emerging	industries,	are	there	lessons	they	have	learned	in	innovating	new	
techniques	when	traditional	manufacturing	methods	do	not	apply?	
b. What	insights	from	traditional	manufacturing	might	help	this	nascent	industry	(i.e.,	
scaling	up	and/or	scaling	out	for	regenerative	medicine)	avoid	potential	problems?			
c. Are	there	unique	features	from	the	regulatory	process	for	medical	products?			
d. What	are	the	implications	for	industry	in	the	unique	business	environment	of	"price	
controls"	for	medical	treatments,	a	world	in	which	the	payers	and	the	consumers	
are	usually	different?	
2. Industry	investment	
a.	What	do	investors	(VCs,	forward-leaning	companies,	etc.)	want	(i.e.,	what	are	they	
waiting	for	to	make	an	investment)?		
b.	How	will	emerging	biotechnology	platforms	be	de-risked	sufficiently	for	industry	to	
commercialize?			
c.	There	has	already	been	significant	activity	addressing	regulatory	barriers	and	well	as	
environmental	risk/	impact	–	therefore	it	will	be	important	to	address	this	question	in	
light	of	those	public	studies	(out	of	JCVI	and	the	Wilson	Center	in	the	area	of	synthetic	
biology)	such	that	MForesight	provides	new	insight	to	this	question.	
3. Technology	transfer	
a.	What	are	the	barriers	to	technology	transfer	from	academia	to	industry	for	these	
specific	fields?	Economic,	technology,	policy,	legal,	capital	expenditure,	governance,	
etc.?	
4. Partnerships	
a.	In	what	ways	can	these	fields	achieve	strategic	partnership?		
b.	What	types	of	industry/academic	or	public/	private	partnerships	might	be	successful	
to	move	basic	research	and	largely	public	investments	into	these	research	areas	into	
higher	TRL	endeavors	that	will	more	directly	lead	to	commercialization?		
5. International	benchmarking	
a.	What	are	the	strengths	of	the	US	capabilities	of	commercializing	biologics?	And	how	
does	this	impact	the	national	and	global	economy?		
b.	How	will	U.S.	lead	the	way,	rather	than	competing	at	the	same	ballgame?		
c.	Are	there	growing	competitive	disadvantages	from	which	we	may	never	catch	up?	
BIBLIOGRAPHY OF EXISTING SOURCES 
• GAO,	Regenerative	Medicine:	Federal	Investment,	Information	Sharing,	and	Challenges	in	an	
Evolving	Field	(link)	
• MATES	
o Advancing	Tissue	Science	and	Engineering:	A	Multi-Agency	Strategic	Plan	(link)	
o 2012	Workshop	on	“Functional	Imaging	for	Regenerative	Medicine”	
http://www.nist.gov/mml/bbd/biomaterials/functional_imaging_regenerative_medicin
e_workshop.cfm		
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o 2007	MATES	workshop	held	at	NSF	“Stem	Cell	Research	for	Regenerative	Medicine	and	
Tissue	Engineering”http://www.wtec.org/stem_cell_workshop/	
• NSF	
o Report	on	the	Global	Assessment	of	Biological	Engineering	&	Manufacturing	(2015)	
www.wtec.org/reports.htm	
o NSF	Biomanufacturing	Workshop	Report	Talloires	2014	Workshop	Proceedings_FINAL		
o NSF	Biomanufacturing	Workshop	Report	2013	
http://ase.tufts.edu/terc/workshopreport.pdf	
o A	NCI	and	NSF	Jointly	Supported	Workshop	for	Integrative	Additive	Biomanufacturing	
and	Tumor	Engineering	April	2015	
• NIST	
o Advanced	Manufacturing	Technology	Grants	(AmTech)	Cell	Manufacturing	Consortium	
Workshop	1	2013	
o AmTech	Cell	Manufacturing	Consortium	Workshop	2	2014	
o AmTech	Cell	Manufacturing	Consortium	Workshop	3	2015	
• NIH	Common	Fund	
o NIH	Common	Fund	Center	for	Regenerative	Medicine	Virtual	Workshop	Summary	
Report	–	May	6,	2014	
https://commonfund.nih.gov/sites/default/files/CRM_May_6_2014_Summary_finalv2.p
df	
• NIH	NIAMS	
o Translation	and/or	Commercialization	of	Musculoskeletal	and	Skin	Tissue	Engineering	
and	Regenerative	Medicine	Research	
o Accelerating	Research	Translation	(ART)	in	Musculoskeletal	and	Skin	Tissue	Engineering	
and	Regenerative	Medicine	Competitive	Revision	Award	
• NIH	NIDCR	
o 2008	Workshop	on	“Transforming	Regenerative	Medicine:	An	Interdisciplinary	
Approach”	https://www.nidcr.nih.gov/NR/rdonlyres/9EAFDE6C-7F0B-4218-8AC2-
C16037AF53F9/0/Final_Report_Transforming_Regenerative_Medicine1.pdf		
• California	Institute	for	Regenerative	Medicine		
o Commissioned	Studies	https://www.cirm.ca.gov/about-cirm/cirm-
publications#commissioned	
§ Investing	in	translational	research	to	produce	clinical,	commercial	and	financial	
outcomes	(2013)		
§ Updated	economic	impact	report	(2012)		
§ Report	of	the	CIRM	External	Advisory	Committee		
§ Coverage,	Cost-Control	Mechanisms,	and	Financial	Risk-Sharing	Alternatives	of	
High-Cost	Health	Care	Technologies		
§ Supporting	Diversity	in	Research	Participation:	A	Framework	for	Action		
§ Economic	Impact	of	Research	Funded	by	the	California	Institute	for	
Regenerative	Medicine	(2010)		
o Publications	from	CIRM	Science	and	Policy	Meetings	and	Workshops	
https://www.cirm.ca.gov/about-cirm/publications-cirm-meetings-and-workshops	
§ Key	Tools	and	Technology	Hurdles	in	Advancing	Stem-Cell	Therapies		
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§ International	Regulatory	Considerations	on	Development	Pathways	for	Cell	
Therapies		
§ Creating	a	Cell	Therapy	Manufacturing	Center	of	Excellence		
§ Breaking	the	Bottleneck:	Deriving	Definitive	Hematopoietic	Stem	Cells	from	
Human	Pluripotent	Stem	Cells		
§ Engineering	Strategies,	Opportunities,	and	Challenges	for	Tissue	Repair	and	
Regeneration:	CIRM	Workshop	Summary	and	Recommendations	
§ Executive	summary	of	the	tissue	engineering	workshop		
§ Cell	Therapies	for	Parkinson’s	Disease	from	Discovery	to	Clinic		
§ Alpha	Stem	Cell	Clinics:	Delivering	a	New	Kind	of	Medicine		
§ Critical	Path	Workshop:	2013	CIRM	Grantee	Meeting		
§ Cerebral	Palsy	Workshop		
§ Human	iPS	Cell	Banking	Workshop		
§ SCNT	Workshop	Report		
§ Cover	letter	from	Alan	Trounson		
§ Summary	and	Recommendations	of	the	CIRM	Autism	Workshop		
§ White	paper:	Translational	Issues	for	hESC-Derived	Therapies		
§ Summary	of	the	Clinical	Trials	Workshop		
§ 2008	Grantee	Meeting	Abstract	Book		
§ CIRM	Cancer	Stem	Cell	Workshop	Summary		
§ CIRM	Predictive	Toxicology	Workshop	Report		
§ Report	of	the	Disease	Team	Workshop	(November	2007)		
§ Stem	Cell	Research:	Charting	New	Directions	for	California	(October	2005)	
Conference	Report		
§ 2007	Annual	CIRM	Scholar	Meeting		
§ DISCUSS	Workshop	Report		
§ Ethical	and	Policy	Considerations	for	A	Pluripotent	Stem	Cell	Resource	Center	
2011	Update	(4/29/11)		
§ CIRM	Diversity	Workshop	Report		
§ Ethical	and	Policy	Considerations	for	a	Pluripotent	Cell	Resource	Center	(PCRC)		
§ Advancing	the	Effective	Research	Oversight:	2010	Regional	Workshops	on	
Regulatory	Compliance	5/11/2010		
§ SCRO	Workshop	Report	6/2008		
§ Advancing	Effective	Research	Oversight:	CIRM’s	Evaluation	Initiative	2/08/07		
§ Advancing	Effective	Research	Oversight:	CIRM’s	Evaluation	Initiative	Regional	
Workshop	Summary	Report	5/10/07		
• Alliance	for	Regenerative	Medicine		
o Quarterly	Data	Report:	Q2	2015	provides	an	in-depth	look	at	regenerative	medicine	and	
advanced	therapies	sector	trends	and	metrics	compiled	from	more	than	580	leading	
therapeutic	companies	worldwide.	http://alliancerm.org/page/arm-quarterly-report	
o Key	Tools	and	Technology	Hurdles	in	Advancing	Stem-Cell	Therapies	
http://alliancerm.org/sites/default/files/Key%20Tools%20and%20Tech%20Hurdles%20i
n%20Advancing%20Stem%20Cell%20Therapies.pdf	
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o Pharma	and	Biotech	Survey	regarding	their	strategies	perspectives	of	regenerative	
medicine	
http://alliancerm.org/sites/default/files/ARM_Pharma_SurveyRept_Mar2014_e.pdf	
• UK		
o House	of	Lords	Report	on	Regenerative	Medicine	2013.	
http://www.publications.parliament.uk/pa/ld201314/ldselect/ldsctech/23/2302.htm		
o Building	on	our	own	potential:	a	UK	pathway	for	regenerative	medicine	A	report	from		
the	Regenerative	Medicine	Expert	Group	2013	–	a	response	to	House	of	Lords	report.	
https://www.gov.uk/government/publications/regenerative-medicine-inquiry-
government-response	
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